



OFFICE OF THE CHANCELLOR
TEL: (858) 534-3135
FAX: (858) 534-4523

9500 GILMAN DRIVE # 0005
LA JOLLA, CALIFORNIA 92093-0005

April 9th, 2019

To: President Janet Napolitano
The Regents of the University of California
Dr. Tannishtha Reya, Department of Pharmacology

Subject: Chancellor's Determination and Rationale for Approval of Compound Provided by Japan Tobacco, Inc.

In compliance with [Regent Policy 2309](#), I have reviewed all relevant information and submit my written approval for this study funded by the Lustgarten Foundation, which involves materials provided by Japan Tobacco.

Dr. Tannishtha Reya has secured funding from Lustgarten Foundation for a research project that requires a compound from Japan Tobacco Inc., a pharmaceutical company operating in the tobacco industry.

In accordance with the policy, a peer review committee was convened and comprised of distinguished faculty from UC San Diego. They completed a review of the scope of work and outlined their recommendation, which is summarized in the attached report.

In consultation with Vice Chancellor for Research Sandra A. Brown, I hereby confirm that my rationale for approving this request is based on the committee's compelling conclusions. A copy of the complete review report is attached.

This letter confirms my approval of this request and satisfies the Regents Policy 2309 requirement for a written determination. This signed approval will be distributed accordingly.

Sincerely,

Pradeep Khosla,
Chancellor

Attachment: Review Committee Report

Route approval to:

Dr. Tannishtha Reya
President Napolitano (via Vice President Arthur Ellis)
The Regents of the University of California (via Vice President Arthur Ellis)

Review Committee Memo to Chancellor Khosla
April 5, 2019

RE-89 Evaluation of Proposed Tobacco Related Research Funding - Dr. Tannishtha Reya, Department of Pharmacology, for Materials provided by Japan Tobacco Pharma

Prepared by Dr. Joan Heller Brown, Professor and Chair Department of Pharmacology UC San Diego

Review Committee

Dr. Joan Heller Brown, Professor and Chair, Department of Pharmacology (Committee Chair)
Dr. Rafael Bejar, Assistant Professor, Division of Hematology and Oncology, Department of Medicine
Dr. Ezra Cohen, Professor, Department of Medicine, Associate Director Translational Sciences
Dr. Jason Sicklick, Associate Professor of Surgery, Surgery

Project:

PI: Dr. Tannishtha Reya

Project Title: Targeting stem cell signals in disease models

Funder: Lustgarten Foundation

Provider of the Compound: Japan Tobacco (JT)

As required by Regent Policy 2309 regarding projects involving funds or materials from tobacco firms, we were asked to serve as the Scientific Review committee for Dr. Tannishtha Reya's study funded by the Lustgarten Foundation, which involves materials provided by Japan Tobacco. The policy states that research proposals to be funded by or including materials from the Tobacco Industry must undergo scientific review by faculty members with expertise in the area of science relevant to the study requiring such review.

In the proposed work directed by Dr. Reya, the specific compound to be used in the study is from Japan Tobacco, an entity operating in the tobacco industry. We were advised that while this study is not being supported by funding from the tobacco industry, Regent Policy 2309 applies because of the potential that research results favoring the materials' use in disease models could provide a significant financial advantage to Japan Tobacco.

The aim of the project is to test whether drugs targeting stem cell signals may block cancer growth.

The committee has reviewed the relevant information provided by Dr. Reya and confirms that there is neither use of tobacco products nor benefit to their development that would accrue to JT Tobacco from this work. Instead, the work focuses on treatment of certain deadly diseases with a high clinical need and uses a compound that is made by JT Tobacco, as well as by other pharmaceutical companies. While the other pharmaceutical companies have this compound available and Dr. Reya has attempted to engage them, none chose to pursue providing the compound for various reasons. JT in contrast has been eager to provide the materials and collaborate in this important research venture funded by the Foundation.

In conclusion, the research is extremely sound and promising results could provide great benefit in moving this strategy forward for patients who have no options. Furthermore, it appears that JT is the only possible source of compound for this work as Dr. Reya has made great effort to explore other

options. None of the documents from Japan Tobacco suggest that the industry sponsor will influence the outcome of the scientific pursuit in any way. Given this, the review committee recommends that the University execute the material transfer agreement and Dr. Reya be permitted to proceed with this project.